Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-03-13
2007-03-13
Russel, Jeffrey Edwin (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S013800, C514S014800, C514S015800, C514S016700, C514S017400, C530S324000, C530S326000, C530S327000, C530S328000, C530S329000
Reexamination Certificate
active
10828151
ABSTRACT:
The subject invention concerns peptide molecules that specifically inhibit the enzymatic function of tyrosine kinases, including the JAK and EGF receptor (EGFR) family of kinases, to autophosphorylate, i.e., to transfer a phosphate group from ATP to an amino acid in the kinase. Phosphorylation of proteins is the most fundamental method for signal transduction among proteins in a cell. Inhibition of tyrosine kinase autophosphorylation activities inhibits the enzyme's signaling and shuts down the functioning pathways originating from the enzyme. The JAK2 and EGFR tyrosine kinases are involved in both inflammatory disorders and cancer. In these disorders, the tyrosine kinases can often be activated in an uncontrolled fashion. The subject application also concerns antibodies that bind to a tyrosine kinase autophosphorylation site. The subject invention also concerns pharmaceutically acceptable formulations of the subject peptides and antibodies, and methods for treating inflammatory and oncological disorders by inhibiting tyrosine kinase signaling in these situations by administering a peptide or antibody of the present invention.
REFERENCES:
patent: 4179337 (1979-12-01), Davis et al.
patent: 5034322 (1991-07-01), Rogers et al.
patent: 5106739 (1992-04-01), Comai et al.
patent: 5346888 (1994-09-01), Lipsky et al.
patent: 5530101 (1996-06-01), Queen et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5625136 (1997-04-01), Koziel et al.
patent: 5693762 (1997-12-01), Queen et al.
patent: 5763585 (1998-06-01), Nag
patent: 5854204 (1998-12-01), Findeis et al.
patent: 5912183 (1999-06-01), Comoglio et al.
patent: 5919455 (1999-07-01), Greenwald et al.
patent: 6180370 (2001-01-01), Queen et al.
patent: 6407213 (2002-06-01), Carter et al.
patent: 2001/0028879 (2001-10-01), Spaner
patent: 2002/0035243 (2002-03-01), Imfeld et al.
patent: 2002/0120100 (2002-08-01), Bonny
patent: 2003/0032594 (2003-02-01), Bonny
patent: 2003/0050455 (2003-03-01), Ruben et al.
Alexander, W. “Suppressors of Cytokine Signaling (SOCS) in the Immune System”Nature Review Immunology, Jun. 2002, pp. 1-7, vol. 2.
Andersson, L. “Significance of Tyrosine Kinases in Cancer: Overview”European Journal of Cancer, 2002, vol. 38, Suppl. 5 S2.
Blalock, J. et al. “Binding of Peptides that are Specified by Complementary RNAs”Biochem. J., 1986, pp. 679-683, vol. 234.
Blume-Jensen, P. et al. “Oncogenic Kinase Signalling”Nature, May 2001, pp. 355-365, vol. 411.
Capdeville, R. et al. “Glivec (STI571, Imatinib), a Rationally Developed Targeted Anticancer Drug”Nature Reviews Drug Recovery, Jul. 2002, pp. 493-502, vol. 1.
De Boer, H. et al. “TheTacPromoter: a Functional Hybrid Derived From thetrpandlacPromoters”Proc. Natl. Acad. Sci. USA, Jan. 1983, pp. 21-25, vol. 80.
Familletti, P. et al. “A Convenient and Rapid Cytopathic Effect Inhibition Assay for Interferon”Methods in Enzymology, 1981, pp. 387-394, vol. 78.
Felgner, P. et al. “Lipofection: A Highly Efficient, Lipid-medicated DNA-transfection Procedure”Proc. Natl. Acad. Sci. USA, Nov. 1987, pp. 7413-7417, vol. 84.
Ferrara, N. et al. “The Biology of VEGF and its Receptors”Nature Medicine, Jun. 2003, pp. 669-676, vol. 9, No. 6.
Hanada, T. et al. “Negative Regulation of Cytokine Signaling by CIS/SOCS Family Proteins and Their Roles in Inflammatory Diseases”Rev. Physiol Biochem Pharmacol, 2003, pp. 72-86, vol. 149.
Kile, B. et al. “The SOCS Box: A Tale of Destruction and Degradation”Trends Biochem. Sci., May 2002, pp. 235-241, vol. 27, No. 5.
Kotenko, S. et al. “Jak-Stat Signal Transduction Pathway Through the Eyes of Cytokine Class II Receptor Complexes”Oncogene, 2000, pp. 2557-2565, vol. 19.
Kohler, G. et al. “Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity”Nature, Aug. 1975, pp. 495-497, vol. 256.
Larsen, L. et al. “Suppressors of Cytokine Signalling: SOCS”APMIS, 2002, pp. 833-844, vol. 110.
Levitzki, A. “Tyrosine Kinases as Targets For Cancer Therapy”European Journal of Cancer, 2002, vol. 38, Suppl. 5, S11-S18.
Merrifield, R.B. “Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide”J. Amer. Chem. Soc., Jan. 31, 1963, pp. 2149-2154, vol. 85.
Ritter, C. et al. “The Epidermal Growth Factor Receptor-tyrosine Kinase: A Promising Therapeutic Target in Solid Tumors”Semin. Oncol., Feb. 2003, pp. 3-11, vol. 30, No. 1, Suppl. 1.
Szente, B. et al. “Structural Requirements For Agonist Activity of a Murine Interferon-gamma Peptide”J. Interferon Cytokine Res., 1996, pp. 813-817, vol. 16.
Tam, J. “Synthetic Peptide Vaccine Design: Synthesis and Properties of a High-density Multiple Antigenic Peptide System”Proc. Natl. Acad. Sci. USA, Aug. 1988, pp. 5409-5413, vol. 85.
Villain, M. et al. “De NovoDesign of Peptides Targeted to the EF Hands of Calmodulin”J. Biol. Chem., Jan. 28, 2000, pp. 2676-2685, vol. 275, No. 4.
Wells, A. “EGF Receptor”Int. J. Biochem. Cell Biol., 1999, pp. 637-643, vol. 31, No. 6.
Xia, L. et al. “Identification of Both Positive and Negative Domains Within the Epidermal Growth Factor Receptor COOH-terminal Region for Signal Transducer and Activator of Transcription (STAT) Activation”J. Biol. Chem., Aug. 23, 2002, pp. 30716-30723, vol. 277, No. 34.
Xu, D. et al. “Systemic Induction of a Potatopin2Promoter by Wounding, Methyl Jasmonate, and Abscisic Acid in Transgenic Rice Plants”Plant Molecular Biology, 1993, pp. 573-588, vol. 22.
Yasukawa, H. et al. “The JAK-binding Protein JAB Inhibits Janus Tyrosine Kinase Activity Through Binding in the Activation Loop”EMBO J., 1999, pp. 1309-1320, vol. 18, No. 5.
Yu, Y. et al. “Direct Identification of a Major Autophosphorylation Site on Vascular Endothelial Growth Factor Receptor Fit-1 that Mediates Phosphatidylinositol 3′-kinase Binding”Biochem J., 2001, pp. 465-472, vol. 358, Part A.
Faasina, G. et al. “Binding of Human Tumor Necrosis Factor α to Multimeric Complementary Peptides”Archives of Biochemistry and Biophysics, Jul. 1, 1992, pp. 137-143, vol. 296, No. 1.
Hobta, A. et al. “Epidermoid Carcinoma-Derived Antimicrobial Peptide (ECAP) Inhibits Phosphorylation by Protein Kinasesin vitro”Cell Biochemistry and Function, 2001, pp. 291-298, vol. 19.
Kelloff, G. J. et al. “Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors as Potential Cancer Chemopreventives”Cancer Epidemiology, Biomarkers and Prevention, 1996, pp. 657-666, vol. 5.
Ohya K-I. et al. “SOCS-1/JAB/SSI-1 Can Bind to and Suppress Tec Protein-Tyrosine Kinase”The Journal of Biological Chemistry, 1997, pp. 27178-27182, vol. 272, No. 43.
Flowers Lawrence
Johnson Howard M.
Mujtaba Mustafa G.
Subramaniam Prem S.
Russel Jeffrey Edwin
Saliwanchik Lloyd & Saliwanchik
University of Florida Research Foundation Inc.
LandOfFree
Inhibitors of autophosphorylation protein kinases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of autophosphorylation protein kinases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of autophosphorylation protein kinases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3744499